Table 2 Prevalence, awareness, treatment and control of hypercholesterolemia (HC) in Astana region, Kazakhstan (total cholesterol ≥6.2 mmol/l)
Men (n = 416) | Women (n = 538) | Both sexes (n = 954) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Prevalence | 95% CI | Cases/All | Prevalence | 95% CI | Cases/All | Prevalence | 95% CI | Cases/All | |
Combined Astana city and Akmol village | |||||||||
Prevalence of HC among all | 28.4% | 24.0–32.7 | 118/416 | 44.1% | 39.8–48.3 | 237/538 | 37.2% | 34.1–40.3 | 355/954 |
Awareness among all cases of HC | 47.5% | 38.3–56.6 | 56/118 | 61.2% | 54.9–67.4 | 145/237 | 56.6% | 51.4–61.8 | 201/355 |
Treatment among all cases of HC | 33.1% | 24.4–41.7 | 39/118 | 44.3% | 37.9–50.7 | 105/237 | 40.6% | 35.4–45.7 | 144/355 |
Treatment among aware | 67.9% | 55.2–80.5 | 38/56 | 71.7% | 64.3–79.1 | 104/145 | 70.7% | 64.3–77.0 | 142/201 |
Control among all cases of HC | 26.3% | 18.2–34.3 | 31/118 | 21.9% | 16.6–27.2 | 52/237 | 23.4% | 19.0–27.8 | 83/355 |
Control among treated | 79.5% | 66.2–92.7 | 31/39 | 49.5% | 39.8–59.2 | 52/105 | 57.6% | 49.5–65.8 | 83/144 |
Astana city (urban, n = 480) | |||||||||
Prevalence of HC among all | 38.2% | 31.7–44.7 | 84/220 | 57.3% | 51.3–63.4 | 149/260 | 48.5% | 44.1–53.0 | 233/480 |
Awareness among all cases of HC | 56.0% | 45.1–66.8 | 47/84 | 72.5% | 65.2–79.7 | 108/149 | 66.5% | 60.4–72.6 | 155/233 |
Treatment among all cases of HC | 36.9% | 26.4–47.4 | 31/84 | 49.7% | 41.5–57.8 | 74/149 | 45.1% | 38.6–51.5 | 105/233 |
Treatment among aware | 63.8% | 49.6–78.1 | 30/47 | 68.5% | 59.6–77.4 | 74/108 | 67.1% | 59.6–74.6 | 104/155 |
Control among all cases of HC | 29.8% | 19.8–39.7 | 25/84 | 24.8% | 17.8–31.9 | 37/149 | 26.6% | 20.9–32.3 | 62/233 |
Control among treated | 80.7% | 65.9–95.4 | 25/31 | 50.0% | 38.3–61.7 | 37/74 | 59.1% | 49.5–68.6 | 62/105 |
Akmol village (rural, n = 474) | |||||||||
Prevalence of HC among all | 17.4% | 12.0–22.7 | 34/196 | 31.7% | 26.2–37.2 | 88/278 | 25.7% | 21.8–29.7 | 122/474 |
Awareness among all cases of HC | 26.5% | 10.8–42.1 | 9/34 | 42.1% | 31.5–52.6 | 37/88 | 37.7% | 29.0–46.4 | 46/122 |
Treatment among all cases of HC | 23.5% | 8.5–38.6 | 8/34 | 35.2% | 25.0–45.4 | 31/88 | 32.0% | 23.6–40.4 | 39/122 |
Treatment among aware | 88.9% | 63.3–114.5 | 8/9 | 81.1% | 67.8–94.3 | 30/37 | 82.6% | 71.2–94.0 | 38/46 |
Control among all cases of HC | 17.7% | 4.1–31.1 | 6/34 | 17.1% | 9.0–25.1 | 15/88 | 17.2% | 10.4–24.0 | 21/122 |
Control among treated | 75.0% | 36.3–113.7 | 6/8 | 48.4% | 29.8–67.0 | 15/31 | 53.9% | 37.5–70.2 | 21/39 |